project overview | the principal investigators | funding agencies & research institutions | news | resources | contact us
 

news & updates

Scott D. Tanner

Scott D. Tanner, PhD


Associate Professor
Institute for Biomaterials and Biomedical Engineering
University of Toronto

 

- Research
- People
- Publications

Relevant Publications from the Tanner Group

Lou X, Zhang G, Herrera I, Kinach R, Ornatsky O, Baranov V, Nitz M, Winnik MA. Polymer-based elemental tags for sensitive bioassays, Angew Chem Int Ed Engl. 2007 May 29;46(32):6111-6114.

Tanner SD, Ornatsky O, Bandura DR, Baranov VI. Multiplex bio-assay with inductively coupled plasma mass spectrometry: Towards a massively multivariate single-cell technology, Spectrochimica Acta Part B: Atomic Spectroscopy, 2007 Mar;62(3):188-195.


More Publications

    


“If cancer stem cells lie at the heart of some cancers, then being able to predict the behavior of tumors and providing effective therapies against them means understanding the abnormal growth pathways within the stem cells themselves.”

- John Dick, Project Leader (UHN)



“The only reason that I'm willing to take a risk on this project is my confidence in the quality and camaraderie of my colleagues.”

- Scott Tanner, Principal Investigator (University of Toronto)



“We're examining DNA not for its well-recognized role as the genetic material to store and transmit genetic information, but rather for its less-known potential to act as a novel cancer diagnostic tool.”

- Yingfu Li, Principal Investigator (McMaster University)



“We're gaining more understanding of cell defects and how to modify them, so that treatment is no longer a shotgun approach, but more like an arrow aimed at a specific target.”

- Mark Minden, Principal Investigator (OCI)

scott d. tanner - university of toronto



(L to R): Xudong Lou, Alexei Antonov, Olga Ornatsky, Vladimir Baranov, Scott Tanner, Robert Kinach, Adrienne Halupa, Sergey Vorobiev, and Dmitry Bandura.






This project was funded by Genome Canada through the Ontario Genomics Institute.

Complementary funding is gratefully acknowledged from:
Ontario Cancer Research Network | National Cancer Institute of Canada
Leukemia and Lymphoma Society (USA) | University of Toronto | MDS Sciex
DVS Sciences Inc. | Parker Life Sciences | Leybold Vacuum GmbH
Materials and Manufacturing Ontario | National Institutes of Health
University Health Network | Cytopeia Inc. | ETP Electron Multipliers | CSL Ltd.
Ontario Institute for Cancer Research | Princess Margaret Hospital Foundation